Aug 2026· Frontiers in Immunology· Vol 17· 0 citations· 156 references
Medicine
TL;DR
This review examines the emerging data on envafolimab and discusses strategies to optimize its therapeutic impact, including combination regimens and personalized approaches.
Abstract
The landscape of immunotherapy in oncology has markedly advanced with the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, fundamentally reshaping cancer treatment by potentiating anti-tumor immune responses. PD-1/PD-L1 blockade agents, such as FDA-approved nivolumab, pembrolizumab, and dostarlimab, have demonstrated significant clinical efficacy across various malignancies. Additionally, investigational agents like envafolimab, a novel PD-L1 inhibitor, are currently under clinical evaluation for efficacy and safety in solid tumors. This review examines the emerging data on envafolimab and discusses strategies to optimize its therapeutic impact, including combination regimens and personalized approaches. Tailoring treatments based on individual genetic, immunological, and microbiome profiles holds the potential to enhance response rates and the durability of outcomes. The integration of these factors is pivotal in advancing the precision and success of immunotherapy in oncology.
CTLA-4 blockade with Ipilimumab or Tremelimumab shows promise, especially combined with PD-1/PD-L1 inhibitors, yielding enhanced antitumor immunity in microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) tumors with high immune infiltration.
Fuyuan Ma, Jingyuan Ma, Yaofan Lu et al.· American Journal of the Medi...· 0 citations
Penpulimab (AK105) is a novel Fc-engineered, humanised IgG₁ monoclonal antibody targeting programmed cell death protein-1 (PD-1). Unlike conventional PD-1 inhibitors, penpulimab has been designed to eliminate Fcγ receptor and complement C1q binding, thereby reducing Fc-mediated effector functions while maintaining anti...
Serina Easmin, Sangita Palai, Sudip Saha et al.· Critical reviews in oncology...· 0 citations
A dual-source PD-L1 framework is proposed to discuss the potential contributions of tumor cell-derived and immune cell-derived PD-L1 to GBM-mediated immunosuppression and therapeutic response and a multilayer resistance model involving the blood–brain barrier, an immunologically cold tumor microenvironment, and compens...
Junlin Lu, Xu-Xin Zhang· Eurasian Journal of Medicine...· 0 citations
Peripheral T-cell lymphomas (PTCL) are rare chemoresistant malignancies with poor outcomes, necessitating novel therapies. The programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) axis is frequently overexpressed in PTCL and represents a potential therapeutic target; however, PD-L1 inhibition has not been explor...
M. Ahearne, Matthew A. Timmins, C. Gaskell et al.· British Journal of Haematolo...· 0 citations
Background/Objectives: Programmed cell death protein 1 (PD-1) is a key immune checkpoint that suppresses anti-tumor T-cell responses and is an established target for cancer immunotherapy. UDIZ-007 is a fully human anti-PD-1 antibody that blocks PD-1/PD-L1 and PD-1/PD-L2 interactions and eradicates MC38-hPD-L1 colon tum...
Gregorio de Jesús Carballo Uicab, Keyla María Gómez Castellano, Frida Daniela Ramírez Villedas et al.· Pharmaceuticals· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
